TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25324220

Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention
Number of subjects: 237

Group type: COMPARATOR
Intervention: Attentional control condition
Number of subjects: 237
Study: 23894426

Group type: EXPERIMENTAL
Intervention: Green exercise (rural environment)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Urban exercise (urban environment)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control condition (urban exercise)
Number of subjects: 75
Study: 21744383

Group type: EXPERIMENTAL
Intervention: Structured autobiographical writing workshop
Number of subjects: 51

Group type: COMPARATOR
Intervention: Reminiscence group (active control condition)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 51
Study: 18623166

Group type: EXPERIMENTAL
Intervention: Body mass measurements (weight, height, body mass)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Lean tissue
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fat tissue
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Change in body mass variables
Number of subjects: 101
Study: 17115317

Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Infrared Coagulation (IRC)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both RBL and IRC
Number of subjects: 94
Study: 15386864

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 18
Study: 11171519

Group type: EXPERIMENTAL
Intervention: CO2 detection thresholds
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: VOC localization thresholds
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal allergies
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CO2 and VOC measures
Number of subjects: 16
Study: 9392401

Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg (single i.m. injection, with a second dose if unsatisfactory response after 48 h)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Amoxicillin clavulanate, 12.5 mg tid (10-day course)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Amoxicillin clavulanate
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 215
Study: 7930480

Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg orally; n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 14
Study: 3064333

Group type: EXPERIMENTAL
Intervention: Titan S air turbine scaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 12
Study: 28926120

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 12 weeks
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 16 weeks
Number of subjects: 131
Study: 27370229

Group type: EXPERIMENTAL
Intervention: eCoFit intervention (20-week multi-component intervention including outdoor training and cognitive mentoring in Phase 1 and smartphone application in Phase 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eCoFit smartphone application (Phase 2)
Number of subjects: 0
Study: 25534579

Group type: EXPERIMENTAL
Intervention: NEUROvitalis (NV) cognitive training
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mentally fit (MF) cognitive training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Waiting list control group (CG)
Number of subjects: 47
Study: 23473061

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic appendectomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Three-port laparoscopic appendectomy
Number of subjects: 102
Study: 20946120

Group type: EXPERIMENTAL
Intervention: Anticipatory nausea (AN)
Number of subjects: 214
Study: 19114761

Group type: EXPERIMENTAL
Intervention: Morphine and Ketorolac administered 1 hr prior to skin incision
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine and Ketorolac administered at peritoneum closure
Number of subjects: 40
Study: 16488321

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg subcutaneous weekly
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 14615702

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 1348

Group type: COMPARATOR
Intervention: SSRI
Number of subjects: 1348
Study: 10915070

Group type: EXPERIMENTAL
Intervention: Heterozygote children (wild type [wt]/Delta32)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Wild type (wt/wt) children
Number of subjects: 457
Study: 8678775

Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium (1 g)
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid (3.1 g)
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium (1 g)
Number of subjects: 1070
Study: 1811428

Group type: EXPERIMENTAL
Intervention: Square wave
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postsynaptic wave
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 120
Study: 6139529

Group type: EXPERIMENTAL
Intervention: Phenobarbitone (20 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenobarbitone
Number of subjects: 60
Study: 30357332

Group type: EXPERIMENTAL
Intervention: G1P[8] rotavirus vaccine (2-3 doses)
Number of subjects: 166
Study: 30156433

Group type: EXPERIMENTAL
Intervention: Contingency management for alcohol
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Contingency management for other drug
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Contingency management for both substances
Number of subjects: 114

Group type: COMPARATOR
Intervention: No contingency management for either substance
Number of subjects: 114
Study: 26839145

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 511

Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab
Number of subjects: 511
Study: 24715424

Group type: EXPERIMENTAL
Intervention: Oligofructose (30 g day(-1) for 6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cellulose (control)
Number of subjects: 22
Study: 22244522

Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm² Baerveldt glaucoma implant)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 105

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C
Number of subjects: 105
Study: 20807969

Group type: EXPERIMENTAL
Intervention: Social intervention
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combined treatment (social intervention + antidepressants)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 123
Study: 18399030

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 30
Study: 14693573

Group type: EXPERIMENTAL
Intervention: ADP receptor antagonist alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ADP receptor antagonist plus IV heparin
Number of subjects: 93

Group type: COMPARATOR
Intervention: No preoperative treatment
Number of subjects: 93
Study: 11964722

Group type: EXPERIMENTAL
Intervention: Dietary antioxidants; specific dosage and duration not available
Number of subjects: 0
Study: 9721148

Group type: EXPERIMENTAL
Intervention: Budesonide enema 2.0 mg/100 mL
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Budesonide enema 8.0 mg/100 mL
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Budesonide enema (both doses)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo enema
Number of subjects: 233
Study: 8052432

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3056816

Group type: EXPERIMENTAL
Intervention: Biosynthetic human proinsulin (assumed potency 4 U/mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 7
Study: 8436094

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU vitamin A and 40 IU vitamin E)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 219500

Group type: EXPERIMENTAL
Intervention: Antacid mixture plus sulpiride
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Sulpiride alone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Antacid mixture alone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 31122876

Group type: COMPARATOR
Intervention: Sleep group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consistent strategy use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep group assignment
Number of subjects: 0
Study: 27838576

Group type: EXPERIMENTAL
Intervention: Snapshot‐Freeze (SSF) with beta-blockers (BB)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Snapshot‐Freeze (SSF) without beta-blockers (non-BB)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard reconstruction (STD) with beta-blockers (BB)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard reconstruction (STD) without beta-blockers (non-BB)
Number of subjects: 140
Study: 26070917

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg orally once daily
Number of subjects: 1717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study: 23606201

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil and folinic acid (OFF)
Number of subjects: 30
Study: 21555689

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 377

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 377
Study: 19412127

Group type: COMPARATOR
Intervention: Absence of LVH (n = 285)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Persistence of LVH (n = 418)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Development of LVH (n = 97)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Regression of LVH (n = 155)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Persistence of LVH
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Absence and regression of LVH at 3 years
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Development of LVH
Number of subjects: 1447
Study: 17145624

Group type: EXPERIMENTAL
Intervention: Factor V Leiden (FVL) mutation
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Prothrombin (PT) G20210A mutation
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Miscarriage and preeclampsia
Number of subjects: 5000
Study: 15180019

Group type: COMPARATOR
Intervention: Midazolam (starting dose of 0.1 mg/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (starting dose of 0.25 microg/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (starting dose of 0.5 microg/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 microg/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.25 microg/kg/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ramsay score of 1
Number of subjects: 20
Study: 11843991

Group type: EXPERIMENTAL
Intervention: Medicare Alzheimer's Disease Demonstration (MADDE)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 412
Study: 9766304

Group type: EXPERIMENTAL
Intervention: tirilazad mesylate
Number of subjects: 31

Group type: COMPARATOR
Intervention: vehicle (control)
Number of subjects: 31
Study: 7817169

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no heparin prophylaxis)
Number of subjects: 48
Study: 3043128

Group type: EXPERIMENTAL
Intervention: Cytoprotective antacidum (226 mval acid‐neutralisation‐capacity per day's dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine (2x 400 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Initial combination treatment of antacidum with Cimetidine for 1 week, followed by antacidum
Number of subjects: 60
Study: 30788892

Group type: EXPERIMENTAL
Intervention: Hypoxic training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 24
Study: 28336937

Group type: COMPARATOR
Intervention: FCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: FCM-miniR (mitoxantrone with low-dose rituximab)
Number of subjects: 200
Study: 25415549

Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS + RTP
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham-rTMS + RTP
Number of subjects: 21
Study: 23433258

Group type: EXPERIMENTAL
Intervention: UC simulation-based skills training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Video instruction before performance testing
Number of subjects: 64
Study: 21666275

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nurse-led supportive care
Number of subjects: 20
Study: 19329405

Group type: EXPERIMENTAL
Intervention: High-dose multivitamin and mineral supplement (MMS)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Calcium 162 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low-dose MMS
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 16394956

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO) - 1000 mg vitamin C and 300 mg RRR‐alpha‐tocopheryl acetate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebos (PL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (AO and PL)
Number of subjects: 22
Study: 15280133

Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 240

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 240
Study: 11345029

Group type: EXPERIMENTAL
Intervention: Ukrain 50 mg (5 mg every second day for a total of 10 injections)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ukrain 100 mg (10 mg injections)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Symptomatic corrective therapy (control group)
Number of subjects: 75
Study: 8842603

Group type: EXPERIMENTAL
Intervention: Glimepiride 1 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 1622919

Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg twice a day for 7 1/2 days starting the evening before the abortion
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Erythromycin in women positive for C. trachomatis
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo in women positive for C. trachomatis
Number of subjects: 432
Study: 6691563

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (4‐5 micrograms/kg intramuscularly 45‐90 min before induction)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction) + Glycopyrrolate (4‐5 micrograms/kg intramuscularly 45‐90 min before induction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 30021588

Group type: EXPERIMENTAL
Intervention: Best current treatment plus ultrasound-guided intra-articular hip injection of corticosteroid (triamcinolone acetonide 40 mg) with 1% lidocaine hydrochloride
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Best current treatment plus ultrasound-guided intra-articular hip injection of 1% lidocaine hydrochloride alone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Best current treatment alone
Number of subjects: 204
Study: 28807059

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) dietary intervention, consisting of a two-hour dietary education session in early pregnancy.
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 625
Study: 25908114

Group type: EXPERIMENTAL
Intervention: Midregional proadrenomedullin (MR‐proADM)
Number of subjects: 2071

Group type: COMPARATOR
Intervention: Troponin (cTnI)
Number of subjects: 2071
Study: 24132714

Group type: EXPERIMENTAL
Intervention: Repaired tetralogy of Fallot in women
Number of subjects: 272
Study: 19915912

Group type: EXPERIMENTAL
Intervention: PEEP (PEEP = 5 cmH(2)O)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ZEEP (PEEP = 0 cmH(2)O)
Number of subjects: 30
Study: 18338275

Group type: EXPERIMENTAL
Intervention: 3‐in‐1 block with 40 ml of 0.25% bupivacaine 30‐minutes before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simple needle puncture at the operation site 30‐minutes before surgery
Number of subjects: 30
Study: 16901610

Group type: EXPERIMENTAL
Intervention: One-handed chest compressions
Number of subjects: 62

Group type: COMPARATOR
Intervention: Two-handed chest compressions
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Preference for technique
Number of subjects: 62
Study: 12801491

Group type: EXPERIMENTAL
Intervention: Continuous PC6 acupressure
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 301
Study: 10983550

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 483
Study: 7574952

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin according to the 'Hammersmith' regimen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2117207

Group type: EXPERIMENTAL
Intervention: Inositol (INO) supplementation (70‐100 mg/kg/day)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Inositol (INO) supplementation
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control (glucose supplementation)
Number of subjects: 230
Study: 7281089

Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 4
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference cigarette without anti-smoking filter
Number of subjects: 12
Study: 30739376

Group type: EXPERIMENTAL
Intervention: SMOFlipid
Number of subjects: 89

Group type: COMPARATOR
Intervention: ClinOleic
Number of subjects: 89
Study: 28682887

Group type: EXPERIMENTAL
Intervention: Atropine 0.5% eyedrops (ATE)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 25511794

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (oseltamivir alone)
Number of subjects: 0
Study: 24475598

Group type: EXPERIMENTAL
Intervention: Blended teaching intervention (Internet-based tutorials + traditional lectures)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional face-to-face classroom teaching
Number of subjects: 112
Study: 21495829

Group type: EXPERIMENTAL
Intervention: bisoprolol/hydrochlorothiazide 5/6.25 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: amlodipine/valsartan 5/160 mg
Number of subjects: 180
Study: 20070722

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no endometrial biopsy)
Number of subjects: 115
Study: 17295576

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127
Study: 15323587

Group type: EXPERIMENTAL
Intervention: Quetiapine (300 mg/day, titrated upward)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11257268

Group type: COMPARATOR
Intervention: GG genotype
Number of subjects: 387

Group type: COMPARATOR
Intervention: DD genotype
Number of subjects: 387

Group type: COMPARATOR
Intervention: DG genotype
Number of subjects: 387
Study: 9875113

Group type: EXPERIMENTAL
Intervention: Intracoronary GTN (0.2 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ISDN spray (0.8 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sublingual GTN capsule (0.8 mg)
Number of subjects: 96
Study: 9054791

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (graded activity and cognitive restructuring)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 60
Study: 1686106

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study: 7267929

Group type: EXPERIMENTAL
Intervention: Conditioning group (CS+ and CS- stimuli with electrical shock)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning group (CS+ and CS- stimuli during extinction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phobic group (feared and non-feared cues)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning group (heart rate responses during acquisition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning group (heart rate responses grouped into 2 trial blocks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioning group (heart rate responses during extinction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phobic group (heart rate responses to feared and unfeared cues)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (responses to neutral cues)
Number of subjects: 0
Study: 31533823

Group type: EXPERIMENTAL
Intervention: Yoga therapy (60 min sessions for 8 weeks)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Weekly reminder e-mails
Number of subjects: 128

Group type: COMPARATOR
Intervention: Wait-list control group (receiving yoga 9 weeks later)
Number of subjects: 128